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http://dx.doi.org/10The genomic events responsible for the pathogenesis of relapsed adult B-lymphoblastic leuke-
mia (B-ALL) are not yet clear. We performed integrative analysis of whole-genome, whole-
exome, custom capture, whole-transcriptome (RNA-seq), and locus-specific genomic assays
across nine time points from a patient with primary de novo B-ALL. Comprehensive genome
and transcriptome characterization revealed a dramatic tumor evolution during progression,
yielding a tumor with complex clonal architecture at second relapse. We observed and vali-
dated point mutations in EP300 and NF1, a highly expressed EP300-ZNF384 gene fusion, a
microdeletion in IKZF1, a focal deletion affecting SETD2, and large deletions affecting
RB1, PAX5, NF1, and ETV6. Although the genome analysis revealed events of potential bio-
logical relevance, no clinically actionable treatment options were evident at the time of the sec-
ond relapse. However, transcriptome analysis identified aberrant overexpression of the
targetable protein kinase encoded by the FLT3 gene. Although the patient had refractory dis-
ease after salvage therapy for the second relapse, treatment with the FLT3 inhibitor sunitinib
rapidly induced a near complete molecular response, permitting the patient to proceed to a
matched-unrelated donor stem cell transplantation. The patient remains in complete remis-
sion more than 4 years later. Analysis of this patient’s relapse genome revealed an unexpected,
actionable therapeutic target that led to a specific therapy associated with a rapid clinical
response. For some patients with relapsed or refractory cancers, this approach may indicate
a novel therapeutic intervention that could alter outcome. Copyright  2016 ISEH - Inter-
national Society for Experimental Hematology. Published by Elsevier Inc. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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.1016/j.exphem.2016.04.011B-lymphoblastic leukemia (B-ALL) is the most common
acute leukemia occurring in children, but it is more rare
in adults [1]. It is generally a sporadic, noninherited disease
in children, though recent genome-wide association studies
have identified susceptibility loci including GATA3,atology. Published by Elsevier Inc. This is an open access article under the
604 M. Griffith et al./ Experimental Hematology 2016;44:603–613ARID5B, CEBPE, ETV6, and IKZF1 [2–4]. Additional
studies have implicated rare TP53 [5], IKZF1 [6], and
PAX5 [7] germline mutations that can confer susceptibility
to B-ALL. Early genomic studies of B-ALL using cytoge-
netics or array-based technologies established a high fre-
quency of chromosomal alterations, ranging from focal
copy number alterations (e.g., IKZF1) to large-scale inter-
chromosomal rearrangements (e.g., BCR-ABL, ETV6-
RUNX1) and genome-wide aneuploidy, which have been
used to classify and risk-stratify patients [8,9]. More recent
next-generation sequencing-based approaches have identi-
fied additional recurrent mutations and fusion events
involved in the pathogenesis of childhood B-ALL [10,11].
Specific pathways have emerged as being recurrently
altered in B-ALL, implicating impaired lymphoid develop-
ment (PAX5, EBF1, IKZF1), altered cell cycle maintenance
(CDKN2A, CDKN2B, RB1), and activated kinase signaling
(JAK2, ABL1, IL7R, FLT3) [6]. Analysis of relapsed ALL
cases has identified mutations in TP53, NT5C2, and
CREBBP that could influence treatment response and prog-
nosis [12–15]. These studies have provided valuable in-
sights into the molecular pathogenesis of B-ALL;
however, they have primarily focused on pediatric patients.
The frequency of genomic alterations and corresponding tu-
mor complexity increase with age and treatment outcomes
in adults remain distinctly inferior to those in children [16].
To date, no pilot studies or case studies have been per-
formed to assess the clinical impact of whole-genome
sequencing (WGS), whole-exome sequencing, and whole-
transcriptome sequencing (RNA-seq) analysis in patients
with relapsed adult B-ALL.Methods
Study design, sequencing, and data analysis
Bone marrow biopsy specimens and normal skin samples were ob-
tained from a single patient at nine distinct time points spanning
4,024 days from diagnosis. The subject provided written informed
consent on a form that contained specific language authorizing
WGS and data sharing. All genomic testing was done in a research
environment because no Clinical Laboratory Improvement
Amendments (CLIA)-approved facility was available at the time
of relapse (mid-2011) to create or validate results. However, the
consent document allowed for the return of results to the patient
and treating physician if they were thought to be clinically action-
able. This consent procedure was approved by the Washington
University School of Medicine Human Research Protection Office
(HRPO) on October 23, 2006 and has been renewed annually
thereafter. Because the second relapse sample occurred after an
allograft from a sibling donor, we needed to flow enrich tumor
cells from the ‘‘blast gate’’ to reduce contamination from the allo-
graft donor, which would have confounded the sequencing results
(Supplementary Methods, online only, available from www.
exphem.org). WGS, whole-exome sequencing, and RNA-seq
were performed using library construction and capture hybridiza-
tion methods described previously [17,18]. Alignment of WGS
and whole-exome data was performed using the GenomeModeling System (GMS) essentially as described in Griffith
et al. [18]. Germline and somatic variant detection was performed
using multiple tools for each type of variant, including single
nucleotide variants (SNVs), small insertions and deletions, large
amplifications and deletions, and structural variants. Validation
of somatic variants and deep sequencing assessment at all time
points was performed by custom hybrid capture sequencing using
a NimbleGen (Roche) probe design. This reagent targeted 5,628
regions of interest identified by WGS of the patient’s second
relapse. Analysis of RNA-seq data, including read alignment, esti-
mation of transcript abundance, and fusion detection, was con-
ducted essentially as described previously [19].Results
Case report
A 25-year-old white male presented with a 2-month history
of fatigue, bone pain, night sweats, and frequent upper res-
piratory infections. There was no family history of cancer
or leukemia. A complete blood count revealed a white blood
cell count of 2,700 cells/mL, a hemoglobin level of 9.8 g/dL,
and a platelet count of 269,000/mL. A bone marrow biopsy
showed O95% cellular marrow. The aspirate revealed
O95% blasts. Flow cytometry was notable for coexpression
of CD10/19/33/34/79a, HLA-DR, and TdT, with absent
expression of myeloperoxidase. CD20 was negative. A diag-
nosis of acute B-ALL was made. Cytogenetics showed a
46,XY,del(12)(p13) karyotype in 4/25 metaphases
(Supplementary Figure E1A, online only, available at
www.exphem.org). Fluorescence in situ hybridization
(FISH) results for KMT2A (MLL) deletions, ETV6-RUNX1
(TEL/AML1) fusion, and BCR-ABL1 fusion were all nega-
tive. Cerebrospinal fluid (CSF) analysis demonstrated no ev-
idence of central nervous system involvement. The patient
was treated with a multidrug induction regimen according
to Cancer and Leukemia Group B protocol 8811, which
yielded a complete remission. He went on to receive postre-
mission intensification and subsequently completed mainte-
nance chemotherapy for a total of 2 years of chemotherapy.
Central nervous system prophylaxis consisted of eight doses
of intrathecal chemotherapy with methotrexate.
His first relapse was documented in the bone marrow
64 months after the initial diagnosis, when the patient pre-
sented with bone pain and fatigue. CSF studies were again
negative. The blast immunophenotype was similar to his
initial presentation, with the addition of partial (dim)
CD52 expression. Cytogenetics showed a 46,XY karyotype
in 20/20 metaphases. He was treated with hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexametha-
sone (hyper-CVAD) chemotherapy for four cycles (B /
A / B / A) and intrathecal chemoprophylaxis (four
doses of methotrexate). The patient subsequently under-
went matched (12/12) sibling donor bone marrow trans-
plantation while in a second complete remission after
conditioning with total body irradiation (1,320 cGy),
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(120 mg/kg). He was treated with standard methotrexate
and tacrolimus for graft-versus-host disease (GVHD) pro-
phylaxis. The posttransplantation course was complicated
by acute skin GVHD, which was successfully treated
with corticosteroids and etanercept. Subsequently, the pa-
tient was weaned off tacrolimus and maintained on siroli-
mus for 2 years after transplantation.
The patient’s second relapse was documented in the
bone marrow 102 months after the initial diagnosis, when
he presented with mild pancytopenia and bone pain. CSF
studies were negative for malignant cells. The immunophe-
notype was again positive for CD10 (partial)/19/34/79a.
CD20 and TdT were negative. CD33 and CD52 were not
tested. Cytogenetics demonstrated the 46,XY,del(12)(p13)
lesion in 5/20 metaphases (Supplementary Figure E1B, on-
line only, available at www.exphem.org). FISH with ETV6
break-apart probes revealed a 12p deletion in 92/200
nuclei. ETV6-RUNX1 (TEL/AML1) FISH using break-
apart probes suggested that this deletion did not correspond
to an ETV6-RUNX1 (TEL-AML1) fusion (Supplementary
Figure E1C, online only, available at www.exphem.org).
The patient was treated with ifosfamide and etoposide
with concurrent filgrastim, followed by a donor lympho-
cyte infusion and four doses of intrathecal methotrexate.
He developed severe pancytopenia and grade IV enteritis
complicated by sepsis. A repeat marrow examination
1 month after recovery from salvage revealed 7% lympho-
blasts (based on both morphology and flow cytometry) and
3/20 metaphases were positive for del(12)(p13). FISH with
the ETV6 break-apart probes revealed a 12p deletion in 21/
200 nuclei, consistent with persistent, refractory disease.
Molecular chimerism studies demonstrated 81% donor
and 19% recipient cells. The patient was started on a
low-intensity maintenance regimen of 6-mercaptopurine,
sirolimus, weekly methotrexate, monthly vincristine (only
one dose was administered), and dexamethasone (days 1–
4 of 28). No other viable treatment options were available
and the patient experienced clinical deterioration with
progressive pancytopenia, transfusion dependence, and
fatigue.
Genome analysis
The patient (hereafter referred to as ALL1) consented for
WGS on an institutional review board-approved protocol.
We performed a combination of genotype microarray anal-
ysis, expression microarray analysis, WGS, whole-exome
sequencing, RNA-seq, custom capture sequencing, quanti-
tative polymerase chain reaction (qPCR), and quantitative
interphase FISH. Although the immediate analysis focused
on the second relapse sample, we were ultimately able to
obtain 18 samples from nine time points throughout disease
progression to better understand the evolution of this tumor
over time (Fig. 1A; Supplementary Table E1, online only,
available at www.exphem.org). The specific advantages ofeach technology were leveraged to create a comprehensive
combinatorial analysis of the tumor, leading to the develop-
ment of custom disease-monitoring methods (Fig. 1B;
Supplementary Figures E2–E12; Supplemental Tables
E2–E4, online only, available at www.exphem.org). Anal-
ysis began with the search for clinically relevant somatic
mutations in the WGS and whole-exome data of the second
relapse. Variant candidates identified in these data were
used to design a custom capture reagent (Methods). This
capture reagent was used to perform deep (w800–900)
validation sequencing for variants discovered by WGS or
exome and, later, to assess the presence of each variant at
additional samples/time points not previously sequenced
(Supplementary Table E2). We identified events that per-
sisted throughout the course of the disease, suggesting
that they were present in the original founding clone. We
also observed variants that were lost during disease pro-
gression and variants that were acquired or enriched during
progression (Supplementary Figures E11 and E12). Based
on these observations, we inferred that at least six distinct
subclones existed at some point during the disease.
Although the data obtained were insufficient to create a
complete model of clonal evolution [17], we had sufficient
data to conclude that a dramatic shift in clonal architecture
occurred between the initial presentation and the second
relapse. Potentially relevant somatic variants were identi-
fied in the second relapse by integrated analysis of all
data using multiple algorithms for detection, annotation,
and visualization of each type of variant (Fig. 2;
Supplementary Table E3; Supplemental Methods, online
only, available at www.exphem.org). All notable somatic
variants are summarized in Table 1 and extensive additional
details of the genome analysis are provided in the
Supplementary Results, Supplementary Figures E13–E40,
and Supplementary Tables E3–E7 (online only, available
from www.exphem.org). Germline variant analysis was
also performed but did not reveal any established candi-
dates for susceptibility to B-ALL. Although the genome
analysis led to the identification of several events relevant
to the biology of this tumor, none suggested specific treat-
ment strategies once the patient was determined to have re-
fractory disease after salvage therapy.
Transcriptome analysis
Several transcriptome analyses and methods for integration
of RNA-seq data with WGS and exome data were devel-
oped during this study (Supplementary Materials, online
only, available from www.exphem.org). Comparison of
expression data from the second relapse to several B-ALL
sample cohorts was used to identify possible outlier expres-
sion of genes (Methods; Fig. 3). Sample cohorts for com-
parison consisted of sorted blood cells from healthy
donors and 207 additional B-ALL tumors from pediatric
patients. Based on predictive analysis of microarrays and
outlier clustering of microarray gene expression data
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Figure 1. Study overview. (A) Timeline depicting sample collection during the course of disease treatment and progression. Each sample profiled by one of
five approaches is indicated as a box placed along a timeline representing the patient’s disease course. Time points are indicated in days, with day 0 repre-
senting the day of B-ALL diagnosis. Coloring of each box depicts the type of molecular profiling applied to that sample. Tissue details are encoded in the
abbreviated sample names. Use of ‘‘A’’ or ‘‘I’’ in sample names indicates expected disease status (active or inactive, respectively). The most comprehensively
profiled sample used for much of the mutation discovery described in this work was ‘‘SB_d3072_A,’’ a sorted blast sample (CD45/CD19þ/CD34þ) ob-
tained from marrow at the time of second relapse on day 3,072. At the time of publication, the patient had achieved a complete response and had been disease
free forw4 years. For additional details on each sample and data type generated, refer to Supplementary Table E1. (B) Overview of the integrated analysis
approach used in this case, along with simplified depictions of key analysis activities.
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rather clustered strongly with the ‘‘R5’’ subset of ALL sam-
ples [10,20,21]. To identify expression outliers, a multistep
filter approach was taken, selecting for differentially ex-
pressed, clinically actionable, and druggable genes usinga combination of statistical thresholds and the Drug–Gene
Interaction database [22,23] (Methods). The fms-related
tyrosine kinase FLT3 had an estimated transcript abundance
that was several orders of magnitude above the other three
druggable candidates that were identified (PDGFRB, WT1,
Table 1. Notable variants identified in the second relapse
Variant Variant information Description
EP300 p.P250H Missense mutation in third exon (NM_001429);
22:41521887(C/A)
This mutation was detected in WGS, whole-exome, and
custom capture data and was validated by cDNA cloning
and Sanger sequencing. This mutation is observed at high
VAF in the primary and at relapse 1 and relapse 2. The high
VAF suggests that this mutation is heterozygous and is an
early/initiating event present in all tumor cells. Expression
of this mutation was observed in the RNA-seq data for
relapse 2.
EP300 p.P252S Missense mutation in third exon (NM_001429);
22:41521892(C/T)
The features of this mutation very closely mirror those of the
p.P250H mutation described above. Both EP300 mutations
are in linkage with each other and with the EP300-ZNF384
fusion event described below.
NF1 p.R2258* Nonsense mutation in the 45th exon (NM_001042492);
17:29665110(C/T)
This mutation is predicted to result in loss of function by
introduction of a stop codon. This position falls within an
‘‘Armadillo-type fold domain’’ (IPR016024). Observed at
65% VAF in relapse 2, this variant is heterozygous, but a
subclone exhibits a copy neutral LOH event leading to
O50% VAF (see NF1 LOH event below). This mutation is
not detected in the primary and appears to have been
acquired (or selected from a rare subclone) between primary
and relapse 1. Expression of this mutation was observed in
the RNA-seq data for relapse 2.
NF1 LOH 17q copy neutral LOH resulting in increased frequency of
NF1 p.R2258*; 17:26000000-81165572
The q arm of chromosome 17 exhibits copy neutral LOH
affecting the NF1 locus and many others. Based on the
magnitude of LOH observed in the WGS data, this LOH
event is likely subclonal, affecting w30% of cells in the
second relapse. RNA-seq data show preferential expression
of the mutant copy of NF1 (p.R2258*).
SETD2 p.R2510fs 14 bp deletion affecting the 20th exon (NM_014159);
3:47059121-47059134
(GGAGTACCTTGCGA/-)
This mutation is a predicted to result in loss of function by
introducing a frame-shift mutation. The 14 bp deletion spans
the donor splice site of SETD2 exon 20. This position falls
within an ‘‘SRI, Set2 Rpb1 interacting’’ domain
(IPR013257). This mutation is only observed in relapse 2
and was not detected in primary or relapse 1.
SETD2 focal deletion
(3p21.31)
2.36 Mb deletion; 3:45750000-48110000 A deletion affecting SETD2 was observed by CNV analysis
of WGS coverage data. LOH is observed in heterozygous
SNPs from the region. Both CNVand LOH analyses suggest
that this event is subclonal in relapse 2.
IKZF1 (Ikaros) focal
deletion
80 kb deletion affecting the last 5 exons of IKZF1;
7:50400000-50480000
This mutation is predicted to result in loss of function by
deleting 5 of 8 exons of IKZF1. WGS CNV and LOH
analyses suggest that this deletion is a heterozygous loss
present in all tumor cells in primary and relapse 2.
RB1 large deletion
(13q14.13-13q14.3)
4.80 Mb deletion; 13:46900000-51700000 This mutation is predicted to result in loss of function by
deletion of the entire RB1 locus. WGS CNV and LOH
analyses suggest that this deletion is a heterozygous loss
present in all tumor cells at relapse 2.
ETV6 large deletion
(12p13.2-12p12.3)
4.99 Mb deletion affecting ETV6 (TEL) and CDKN1B;
12:10760000-15750000
This mutation is predicted to result in loss of function by
deletion of the entire ETV6 locus. WGS CNV and LOH
analyses suggest that this deletion is a heterozygous loss
present in all tumor cells at relapse 2.
10q24.1-10q24.33 large
complex deletion
7.82 Mb complex deletion affecting TLX1, NFKB2, SUFU,
and NT5C2; 10:97420000-105240000
This region contains complex deletions and rearrangements
with multiple breakpoints. Some portions of the region
appear to exhibit heterozygous loss, whereas others exhibit
homozygous loss. These events appear to be present in all
tumor cells at relapse 2. This region also results in a SUFU-
TBX19 translocation and ADCY10-CC2D2B translocation.
9p deletion (PAX5) 38.50 Mb deletion; 9:200000-38700000 This large deletion affects multiple cancer genes, including
some tumor suppressors. Both CNV and LOH analyses
suggest that this event is subclonal in relapse 2. Cancer
genes affecteda: CD274, CDKN2A, FANCG, JAK2, MLLT3,
NFIB, PAX5, PDCD1LG2, and PSIP1.
(continued)
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Table 1. (continued )
Variant Variant information Description
EP300-ZNF384 fusion Interchromosomal translocation t(12;22)(p13;q13);
break points:
22:41535555-41536555
12:6784786-6785786
A DNA translocation within the introns of EP300 and
ZNF384 results in a fusion gene that was confirmed as
expressed in relapse 2 by RNA-seq. The fusion gene cDNA
sequence was validated by full-length cloning and Sanger
sequencing. qPCR established this fusion as an early
initiating event present in the dominant clone of primary,
relapse 1, and relapse 2 disease. Full-length cDNA
sequencing confirmed that the open reading frame is
maintained. A fusion protein consisting of the C-terminal
and N-terminal portions of EP300 and ZNF384 is predicted.
The fusion sequence also contained both EP300 missense
mutations described above.
FLT3 overexpression Aberrantly high RNA expression; 13:28577410-28674729 High expression of FLT3 was observed within the RNA-seq
data of relapse 2. Comparison with additional RNA-seq data
from sorted blood lineage cells from healthy donors also
suggested high expression in the patient. Comparisons with
microarray data from w200 B-ALLs suggested that FLT3
expression was also high compared with other tumors.
XBP1 focal deletion 13 kb deletion affecting the first exon of XBP1;
22:29195159-29207958
This focal deletion was identified by SV analysis with
apparent read support in WGS and exome data. Competitive
realignment provided evidence that this deletion is
heterozygous and somatic because no deletion-spanning
reads aligned to the reference allele.
CNV 5 copy number variant; LOH 5 loss of heterozygosity
Visualizations and additional supporting data are available for all notable events in the Supplementary Materials (Supplementary Figures E13–E40;
Supplementary Tables E3–E7). All genomic coordinates shown are relative to the human reference genome build GRCh37/hg19.
aCancer genes defined by the Cancer Gene Census.
608 M. Griffith et al./ Experimental Hematology 2016;44:603–613and TUBB3; Fig. 3A). Evaluation of the RNA expression
estimates of FLT3 in ALL1 and controls revealed an aber-
rant overexpression of this gene in the second relapse sam-
ple of ALL1 (Fig. 3B). FLT3 was highly expressed in the
second relapse in both the absolute sense (i.e., compared
with all genes expressed in that tumor; ‘‘ALL1’’ in
Fig. 3C), as well as in the relative sense (i.e., compared
with other B-ALL samples; Fig. 3D). In the second relapse
sample, FLT3 had an estimated expression level (FPKM of
108.0) that placed it within the top 0.51% of all genes
(Supplementary Table E5). FLT3 expression in the second
relapse was also an outlier compared with blood cell types
sorted from healthy donors, including hematopoietic stem
cell and progenitor-enriched CD34þ fractions (Fig. 3B
and 3C), as well as additional B-ALL samples from Kang
et al. 2010 (Fig. 3D) [24]. The overexpression of FLT3
was confirmed orthogonally by evaluation on an exon array
platform (in triplicate) and compared directly with exon
array data from other studies (Methods). Finally, immuno-
histochemical analysis of the bone marrow biopsy obtained
at the second relapse confirmed high-level expression of the
FLT3 protein (CD135) in lymphoblasts (Supplementary
Figure E41, online only, available at www.exphem.org).
We investigated whether cis-acting regulatory mutations
might be increasing FLT3 transcription levels
(Supplementary Materials). To test this, we made use of a
heterozygous C/T single nucleotide polymorphism (SNP)in exon 2 (Methods). We found that, at each time pointd
diagnosis, first relapse, and second relapsedthe relative
contribution of each allele to total FLT3 mRNAwas equiv-
alent, suggesting that cis-acting mutations did not cause
FLT3 overexpression. These data indicate that both FLT3
alleles were massively overexpressed in the second relapse
sample, suggesting that the gene was activated in trans by
an unknown mechanism. PAX5 is a negative regulator of
FLT3 expression in mice [25,26] and its heterozygous dele-
tion in this tumor (Table 1; Supplementary Figure E21)
could be related to the increased expression of FLT3.
Clinical course after initiation of sunitinib therapy
The initial sequencing of this case took 5 weeks from
receipt of the blast cell DNA sample to return of a detailed
report summarizing the WGS, whole-exome, and whole-
transcriptome results (day 3,107; Fig. 4A). Based on the
observation of aberrant FLT3 expression and a lack of
viable alternative therapeutic options, the patient was
offered sunitinib on a compassionate need basis because
of its ability to inhibit signaling from the wild-type FLT3
receptor. Sunitinib is a receptor tyrosine kinase inhibitor
approved by the Food and Drug Administration for the
treatment of renal cell carcinoma. In addition to FLT3, su-
nitinib is reported to inhibit KIT, KDR, FLT4, PDGFRB,
FLT1, PDGFRA, and RET [22,23]. Although it is possible
that the ‘‘off-target’’ activity of this drug could have been
Figure 2. Overview of genomic findings in the second relapse. Shown is a circos plot of the somatic events identified. The outermost ring displays an ideo-
gram highlighting genes outlined in Table 1. The first data track identifies SNVs (black), small insertions (red), and deletions (blue). The next innermost
track displays copy number gains (red) and losses (blue) relative to the normal sample. Deletions targeted for FISH analysis are indicated with an asterisk
(*). The innermost track displays loss of heterozygosity (LOH) as the change in variant allele frequency from normal to tumor cells at germline heterozygous
sites. The center of the ring displays structural variants identified in the DNA from two algorithms (Breakdancer 5 black, Manta 5 red).
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blood cells from 18 healthy individuals (Methods) revealed FLT3 as an important and clinically actionable target. (B) Evaluation of the expression levels
of FLT3 in ALL1 versus the healthy control-derived blood cells reflects a difference of several orders of magnitude. (C) FLT3 expression is an outlier across
all expressed genes in ALL1, a statistical anomaly otherwise observed only in hematopoietic progenitor (CD34þ) cells and at a magnitude several times
higher than in those cells. Legend for control samples: CD14þ (monocytes), CD19þ (B-cells; CD33/CD19þ), CD3þ (T-cells; CD33-/CD3þ), CD34þ
(hematopoietic progenitors), PMN (neutrophils; CD33/CD15þ/CD16þ), and Pro (promyelocytes; CD14/CD15þ/CD16low/). (D) Microarray evalua-
tion of ALL1 and 207 childhood B-ALL samples revealed that FLT3 is more highly expressed in ALL1 than in any other B-ALL sample in the pediatric
study. The three red points shown for ALL1 represent technical replicates run on the same microarray expression platform as the 207 B-ALLs (Affymetrix
Human Genome U133 Plus 2.0 Array; see Methods).
610 M. Griffith et al./ Experimental Hematology 2016;44:603–613relevant for this tumor, the expression of FLT3 (FPKM of
108.0) was substantially higher than any of the other known
targets of the inhibitor. Of these seven additional targets,
only two are expressed above background levels: PDGFRB
(FPKM of 3.2) and FLT4 (FPKM of 2.8; Supplementary
Table E5).
Sunitinib administration (50 mg daily) began on day
3,124. Within 3 days, the patient had a notable improvement
in his sense of well-being. Quantitative interphase FISH forlarge somatic deletions, morphology (blast counts), and deep
sequencing of somatic SNVs were used to track response to
this therapy. By day 3,137 (day 13 of 22 days of sunitinib), a
significant reduction in disease burden was apparent
(Fig. 4B and 4C). At the same time point, the variant allele
frequencies (VAFs) of somatic SNVs dropped from 11.1% at
day 3,107 to 2.0% at day 3,137 (p ! 2.2  1016;
n 5 1,588, paired, two-tailed Wilcoxon test; Fig. 4C). Suni-
tinib was continued for 9 more days, and then the patient
Figure 4. Personalized genomic assays for assessment of tumor burden and response to treatment. Disease burden and evidence for disease clearance prior to
the final MUD allograft were assessed by three orthogonal approaches: VAFs from deep custom capture sequencing for validated somatic SNVs, quantitative
FISH for four somatic large-scale deletions, and qPCR of a somatic EP300-ZNF384 translocation breakpoint found to be a possible early/initiating event in
this tumor. Time points assayed range from the day of initial diagnosis (day 0) to the patient’s most recent follow-up biopsy obtained w2.5 years into his
current sustained remission (day 4,024). (A) VAFs of 1,588 somatic variants are displayed for eight samples across six time points from diagnosis of the
primary B-ALL (day 0), first relapse (day 1,893), and second relapse (day 3,068/3,072). A 40 coverage filter was applied to the primary samples, further
limiting variants to approximately 581 and 270 for the slide and clot, respectively (Methods). (B) Results from quantitative FISH (Methods) are displayed for
four structural deletions utilized to assess tumor burden at the second relapse and in the following weeks. Refer to Supplementary Table E3 for details on each
deletion assayed. Key treatment time points are indicated with black arrows. (C) VAFs of somatic variants used to assess disease clearance at day 3,219 and
day 4,024 are contrasted with their VAFs during refractory disease after salvage therapy (day 3,107) and in the normal skin sample obtained during the first
remission (day 42). The sample from day 3,137 was obtained 13 days after initiation of sunitinib and demonstrates a highly significant reduction in average
VAFs compared with that of day 3,107 (p ! 2.2e-16; n 5 1,588; Wilcoxon signed-rank test). (D) qPCR data representing abundance ð
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2DDCT
p
Þ of the
EP300-ZNF384 breakpoint in genomic DNA are displayed for a dilution series of the day 3,072 relapse sample with an unrelated skin sample (grey), six
disease samples designated by the day of collection, three samples obtained after the MUD transplantation, a matched skin normal obtained in first remission
(day 42), and a skin sample from an unrelated donor who did not have this translocation (used as a reference to measure assay ‘‘noise’’). Note the nonlinear,
square-root-transformed values used for display purposes (Methods).
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ond allograft from a matched-unrelated donor (MUD) on
day 3,151. No samples were obtained between the end of su-
nitinib treatment (day 3,146) and the MUD allograft. How-
ever, a bone marrow biopsy obtained at day 3,219 (68 days
after the MUD allograft) showed complete tumor clearance
by VAF assessment of somatic SNVs; mutation clearance
persisted at day 4,024 (873 days after MUD allograft;
Fig. 4C). The distribution of VAFs for somatic SNVs at
days 3,219 and 4,024 were indistinguishable from the
normal skin sample obtained during the first remission(day 42; Fig. 4C). VAFs of variants detected at day 3,219
and 4,024 were not significantly different from what would
be expected from sequencing errors alone [17]. Finally, a
DNA-based qPCR assay was developed for the EP300-
ZNF384 fusion (Table 1), a possible initiating event in this
tumor [27,28]. We used this assay to monitor levels of the
fusion in bone marrow, blood, and skin samples obtained
at many time points during the disease (Fig. 4D). This assay
was quantitative and revealed a strong correlation with the
mutation burden measured by somatic SNV VAFs. Impor-
tantly, there was no statistical difference in the levels of
612 M. Griffith et al./ Experimental Hematology 2016;44:603–613the EP300-ZNF384 fusion detected between an unrelated
skin sample and any of the bone marrow or blood samples
obtained after the MUD transplantation. Flow cytometry
for minimal residual disease in blood and bone marrow sam-
ples obtained at day 4,024 showed no evidence of persistent
disease. Taken together, these results suggested that, at day
4,024, the patient was in a complete molecular remission.
The patient remains in a remission at this writing
(4þ years after MUD allograft).
All sequence data described in this publication,
including the WGS, whole-exome, RNA-seq, and custom
capture data, have been deposited in the Database of Geno-
types and Phenotypes (dbGAP) [29] (accession:
phs001066.v1.p1; Supplementary Table E8, online only,
available at www.exphem.org).
Discussion
In this study, we used an integrated genomic approach to
evaluate a patient with refractory disease after a second
relapse of adult B-ALL. The analysis suggested a novel
therapy for this patient, which resulted in a clinical
response that served as a bridge to definitive therapy with
an unrelated donor stem cell allotransplantation. The
WGS data and whole-transcriptome data added consider-
ably to what would have been identified with only whole-
exome sequencing or a targeted panel of cancer genes.
Extensive interpretation by an experienced team of analysts
allowed all of these data to be mined rapidly for potential
clinical relevance.
This tumor contained a large number of possible driver
mutations. Potentially relevant loss-of-function events
included multiple mutations involving NF1 and SETD2,
as well as heterozygous losses affecting RB1, ETV6,
PAX5, and IKZF1. Possible gain-of-function events
included a complex mutation involving missense mutations
of EP300, combined with a fusion event between EP300
and ZNF384. Although none of these mutations are thera-
peutic targets, they were valuable for tracking disease
progression and response to treatment. Finally, a likely
gain-of-function event in the form of aberrant overexpres-
sion of FLT3 suggested a druggable target and allowed
for the rational use of an inhibitor of wild-type FLT3 that
would not otherwise have been used in this setting. We
were unable to quantify the reduction of disease burden
that could be attributed definitively to sunitinib treatment
or salvage chemotherapy. Similarly, whereas the rapid
response of the tumor to sunitinib suggested that the tumor
might be hyperresponsive to FLT3 signaling, we cannot
quantify how much this response was related to FLT3 over-
expression or possibly other factors that may influence the
function of FLT3. Although a previous report suggested
that FLT3 inhibition could kill childhood ALL cells selec-
tively with high levels of FLT3 expression [30], the use of
sunitinib in an adult B-ALL case has not been reported
previously. Some preliminary studies have suggested apossible relationship between FLT3 expression and
response to FLT3 tyrosine kinase inhibitors in childhood
ALL, and have suggested that FLT3 overexpression is
associated specifically with the MLL (KMT2A) rearranged
subset of childhood ALL [30–32]. Additional studies in
adult ALL have reported high expression of FLT3 in
MLL rearranged [33,34] or cytogenetically normal patients
[35]. We observed no evidence of rearrangements involving
the MLL region in this tumor (Supplementary Figure E23);
however, Figure 3D includes 21 MLL-rearranged pediatric
B-ALL cases with lower FLT3 expression than observed
in this case. Additional studies will need to be performed
to determine whether sunitinib and the predictive value of
FLT3 expression may play a role in the treatment of other
relapsed adult B-ALL patients and to identify which subset
of patients would be most likely to respond.
Comprehensive analysis of massively parallel
sequencing data from a tumor genome in ‘‘real time’’ re-
mains a great challenge [36]. Lack of optimization in facil-
ities that perform automated analysis and a lack of tools for
report generation make a fast and clinically relevant turn-
around time difficult to achieve. Even with a sophisticated
analysis pipeline, many features of genomic analysis still
require ad hoc approaches, manual review, and consider-
able effort from analysis experts. This tumor was character-
ized mostly by mutations that caused loss-of-function
events that are generally not druggable. In some cases,
these losses may lead to the activation of a pathway that
may be targeted therapeutically, but algorithms to make
these predictions are not yet available. Furthermore, some
types of somatic alterations are still difficult to detect
with current sequencing platforms and analytical ap-
proaches (e.g. indel detection from WGS/exome data,
structural variant detection from WGS data, fusion detec-
tion from RNA-seq data, the identification of aberrant
splicing events, and the detection of integrated viruses).
Each of these limitations results in false-negative results
that may be biologically significant.
Despite these caveats, the comprehensive approach
described for this case may serve as a guide for future
clinical cancer sequencing for patients with limited or no
treatment options using integrated analysis of WGS and
whole-transcriptome data. The data generated for this case
can serve as a reference for future method development and
as an example of a successful application of these principles.Acknowledgments
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